{"id":"AGY-FED-HEALTH-OTHER-030","kind":"order","level":"federal","jurisdiction":"United States (federal); Substance Abuse and Mental Health Services Administration","state":"","metro":"","industry":"","agency":"FED-HEALTH-OTHER","eco":"","issuer":"SAMHSA, HHS","authority":"42 U.S.C. 257a, 290bb-2a; 21 U.S.C. 823(h); Consolidated Appropriations Act, 2023","instrument":"Final Rule, Medications for the Treatment of Opioid Use Disorder, 89 Fed. Reg. 7528 (Feb. 2, 2024)","title":"Medications for the Treatment of Opioid Use Disorder","dateIssued":"2024-02-02","effective":"2024-04-02 (compliance date Oct. 2, 2024)","end":"In force (permanent)","startDate":"2024-04-02","endDate":"","quarters":[],"types":["HC"],"addressees":["opioid treatment programs"],"clause":"To protect the public\u0027s health and reduce the risk of COVID-19 infection among patients and providers, SAMHSA issued flexibilities in the provision of take-home doses of methadone and initiation of buprenorphine via telehealth, including through audio-only platforms, that allowed for continued treatment of OUD with reduced direct patient contact. Each of these flexibilities represented a significant change to previous treatment standards.","enforcement":"42 C.F.R. part 8 certification","functions":["CL clinical dosing","TM telehealth"],"notes":"Post-period instrument saved for HHS\u0027s own characterization of the 2020 flexibilities as significant changes to treatment standards.","sourceUrl":"https://www.govinfo.gov/content/pkg/FR-2024-02-02/pdf/2024-01693.pdf","snapshot":"","fileExists":true,"fileBytes":633204,"grade":"primary","character":"","description":"","collection":"AGY-FED-HEALTH-OTHER","url":"/library/AGY-FED-HEALTH-OTHER-030","exhibitUrl":"/exhibit/AGY-FED-HEALTH-OTHER-030","citation":"SAMHSA, HHS, Final Rule, Medications for the Treatment of Opioid Use Disorder, 89 Fed. Reg. 7528 (Feb. 2, 2024) (Ex. AGY-FED-HEALTH-OTHER-030)","stateName":"","related":[]}